144 related articles for article (PubMed ID: 38113467)
41. The role of minimal residual disease in specific subtypes of pediatric acute lymphoblastic leukemia.
Xue YJ; Wang Y; Jia YP; Zuo YX; Wu J; Lu AD; Zhang LP
Int J Hematol; 2021 Apr; 113(4):547-555. PubMed ID: 33386596
[TBL] [Abstract][Full Text] [Related]
42. Enhanced Risk Stratification for Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: A Children's Oncology Group Report.
DelRocco NJ; Loh ML; Borowitz MJ; Gupta S; Rabin KR; Zweidler-McKay P; Maloney KW; Mattano LA; Larsen E; Angiolillo A; Schore RJ; Burke MJ; Salzer WL; Wood BL; Carroll AJ; Heerema NA; Reshmi SC; Gastier-Foster JM; Harvey R; Chen IM; Roberts KG; Mullighan CG; Willman C; Winick N; Carroll WL; Rau RE; Teachey DT; Hunger SP; Raetz EA; Devidas M; Kairalla JA
Leukemia; 2024 Apr; 38(4):720-728. PubMed ID: 38360863
[TBL] [Abstract][Full Text] [Related]
43. Post-induction Measurable Residual Disease Using Multicolor Flow Cytometry Is Strongly Predictive of Inferior Clinical Outcome in the Real-Life Management of Childhood T-Cell Acute Lymphoblastic Leukemia: A Study of 256 Patients.
Tembhare PR; Narula G; Khanka T; Ghogale S; Chatterjee G; Patkar NV; Prasad M; Badrinath Y; Deshpande N; Gudapati P; Verma S; Sanyal M; Kunjachan F; Mangang G; Gujral S; Banavali S; Subramanian PG
Front Oncol; 2020; 10():577. PubMed ID: 32391267
[No Abstract] [Full Text] [Related]
44. A prospective study of minimal residual disease in childhood B-lineage acute lymphoblastic leukaemia: MRD level at the end of induction is a strong predictive factor of relapse.
Jacquy C; Delepaut B; Van Daele S; Vaerman JL; Zenebergh A; Brichard B; Vermylen C; Cornu G; Martiat P
Br J Haematol; 1997 Jul; 98(1):140-6. PubMed ID: 9233577
[TBL] [Abstract][Full Text] [Related]
45. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.
Jabbour E; Gökbuget N; Advani A; Stelljes M; Stock W; Liedtke M; Martinelli G; O'Brien S; Wang T; Laird AD; Vandendries E; Neuhof A; Nguyen K; Dakappagari N; DeAngelo DJ; Kantarjian H
Leuk Res; 2020 Jan; 88():106283. PubMed ID: 31790983
[TBL] [Abstract][Full Text] [Related]
46. Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome.
Nyvold C; Madsen HO; Ryder LP; Seyfarth J; Svejgaard A; Clausen N; Wesenberg F; Jonsson OG; Forestier E; Schmiegelow K;
Blood; 2002 Feb; 99(4):1253-8. PubMed ID: 11830473
[TBL] [Abstract][Full Text] [Related]
47. Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Giebel S; Labopin M; Socié G; Beelen D; Browne P; Volin L; Kyrcz-Krzemien S; Yakoub-Agha I; Aljurf M; Wu D; Michallet M; Arnold R; Mohty M; Nagler A
Haematologica; 2017 Jan; 102(1):139-149. PubMed ID: 27686376
[TBL] [Abstract][Full Text] [Related]
48. High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.
Cario G; Rhein P; Mitlöhner R; Zimmermann M; Bandapalli OR; Romey R; Moericke A; Ludwig WD; Ratei R; Muckenthaler MU; Kulozik AE; Schrappe M; Stanulla M; Karawajew L
Haematologica; 2014 Jan; 99(1):103-10. PubMed ID: 23911702
[TBL] [Abstract][Full Text] [Related]
49. More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling.
Bader P; Salzmann-Manrique E; Balduzzi A; Dalle JH; Woolfrey AE; Bar M; Verneris MR; Borowitz MJ; Shah NN; Gossai N; Shaw PJ; Chen AR; Schultz KR; Kreyenberg H; Di Maio L; Cazzaniga G; Eckert C; van der Velden VHJ; Sutton R; Lankester A; Peters C; Klingebiel TE; Willasch AM; Grupp SA; Pulsipher MA
Blood Adv; 2019 Nov; 3(21):3393-3405. PubMed ID: 31714961
[TBL] [Abstract][Full Text] [Related]
50. [Effects of minimal residual disease level on day 33 of remission induction and IKZF1 genotype on the survival of children with B-lineage acute lymphoblastic leukemia].
Kuang WY; Zheng MC; Li WL; Yang HX; Zhang BS; Wu P
Zhongguo Dang Dai Er Ke Za Zhi; 2018 Jul; 20(7):538-542. PubMed ID: 30022754
[TBL] [Abstract][Full Text] [Related]
51. Minimal residual disease surveillance at day 90 predicts long-term survival in pediatric patients with T-cell acute lymphoblastic leukemia.
Liu X; Zou Y; Chen X; Wang S; Guo Y; Yang W; Zhang L; Chen Y; Zhang Y; Zhu X
Leuk Lymphoma; 2020 Dec; 61(14):3460-3467. PubMed ID: 32779947
[TBL] [Abstract][Full Text] [Related]
52. Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival.
Logan AC; Vashi N; Faham M; Carlton V; Kong K; Buño I; Zheng J; Moorhead M; Klinger M; Zhang B; Waqar A; Zehnder JL; Miklos DB
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1307-13. PubMed ID: 24769317
[TBL] [Abstract][Full Text] [Related]
53. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol.
Van der Velden VH; Corral L; Valsecchi MG; Jansen MW; De Lorenzo P; Cazzaniga G; Panzer-Grümayer ER; Schrappe M; Schrauder A; Meyer C; Marschalek R; Nigro LL; Metzler M; Basso G; Mann G; Den Boer ML; Biondi A; Pieters R; Van Dongen JJ;
Leukemia; 2009 Jun; 23(6):1073-9. PubMed ID: 19212338
[TBL] [Abstract][Full Text] [Related]
54. Risk-adapted treatment according to minimal residual disease in adult ALL.
Gökbuget N; Kneba M; Raff T; Bruggemann M; Scheuring U; Reutzel R; Hoelzer D
Best Pract Res Clin Haematol; 2002 Dec; 15(4):639-52. PubMed ID: 12617868
[TBL] [Abstract][Full Text] [Related]
55. [Clinical significance of dynamic monitoring the minimal residual disease in childhood B-lineage acute lymphoblastic leukemia by multiparameter flow cytometry].
Guo DD; Zhao WL; Zhang YL; Pang L; Che L; He HL; Chai YH; Ji ZH; Ji XQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1346-51. PubMed ID: 23257430
[TBL] [Abstract][Full Text] [Related]
56. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
Tzortzatou-Stathopoulou F; Papadopoulou AL; Moschovi M; Botsonis A; Tsangaris GT
J Pediatr Hematol Oncol; 2001 Dec; 23(9):591-7. PubMed ID: 11902303
[TBL] [Abstract][Full Text] [Related]
57. The prognostic significance of hematogones in childhood B-cell acute lymphoblastic leukemia.
Arabi S; Yousefian S; Kavosh A; Mansourian M; Nematollahi P
Pediatr Blood Cancer; 2023 Feb; 70(2):e30138. PubMed ID: 36495254
[TBL] [Abstract][Full Text] [Related]
58. Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.
Mannis GN; Martin TG; Damon LE; Andreadis C; Olin RL; Kong KA; Faham M; Hwang J; Ai WZ; Gaensler KML; Sayre PH; Wolf JL; Logan AC
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1030-1036. PubMed ID: 26899561
[TBL] [Abstract][Full Text] [Related]
59. [Long-term outcome of childhood T-cell acute lymphoblastic leukemia treated with modified national protocol of childhood leukemia in China-acute lymphoblastic leukemia 2008].
Liao C; Shen DY; Xu XJ; Xu WQ; Zhang JY; Song H; Yang SL; Zhao FY; Shen HP; Tang YM
Zhonghua Er Ke Za Zhi; 2020 Sep; 58(9):758-763. PubMed ID: 32872717
[No Abstract] [Full Text] [Related]
60. Genomics improves risk stratification of adults with T-cell acute lymphoblastic leukemia enrolled in measurable residual disease-oriented trials.
González-Gil C; Morgades M; Lopes T; Fuster-Tormo F; García-Chica J; Zhao R; Montesinos P; Torrent A; Diaz-Beya M; Coll R; Hermosín L; Mercadal S; González-Campos J; Zamora L; Artola T; Vall-Llovera F; Tormo M; Gil-Cortés C; Barba P; Novo A; Ribera J; Bernal T; De Ugarriza PL; Queipo MP; Martínez-Sánchez P; Giménez A; González-Martínez T; Cladera A; Cervera J; Fernández-Martín R; Ardaiz MÁ; Vidal MJ; Baena Á; López-Bigas N; Bigas A; Maciejewski J; Orfao A; Ribera JM; Genescà E
Haematologica; 2023 Apr; 108(4):969-980. PubMed ID: 36325893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
